Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QSM Iron Mapping in Parkinson's Disease
NCT03675282Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2018
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of [11C]PE2I, ioflupane I-123 in Parkinson's disease (PD), REM sleep behavior disorder (RBD), sponsored by Weill Cornell Medicine. Started Aug 2018; status: completed.
02
Drugs
[11C]PE2Iioflupane I-123
03
Conditions
Parkinson's disease (PD)REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT03675282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675282.